{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-014299","form_type":"8-K","ticker":"XNCR","cik":"0001326732","company_name":"Xencor Inc","filed_at":"2022-09-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.389784+00:00","generated_at":"2026-06-23T11:48:49.707657+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Xencor appoints Nancy Valente to board; Yujiro Hata resigns","bullets":["Nancy Valente, M.D., appointed to Board on Sept 8, 2022; she brings 20+ yrs pharma experience.","Yujiro Hata's resignation accepted by Board on Sept 8, 2022; he served since 2015.","Valente receives initial option grant valued at $550k (Black-Scholes) plus $50k annual cash retainer.","Valente most recently SVP at Genentech/Roche, led global oncology/hematology product development."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-014299","json":"https://secwatch.observer/filing/0001558370-22-014299.json","markdown":"https://secwatch.observer/filing/0001558370-22-014299.md","text":"https://secwatch.observer/filing/0001558370-22-014299.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326732/000155837022014299/0001558370-22-014299-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326732/000155837022014299/xncr-20220909x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T11:48:49.707657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"b784483fbf","claim":"Yujiro S. Hata resigned as Director at Xencor Inc.","evidence_excerpt":"On June 23, 2022, Yujiro S. Hata tendered his offer of resignation from the Board of Directors (the “Board”) of Xencor, Inc. (the “Company”), subject to the Board’s acceptance of his resignation. On September 8, 2022, the Board accepted Mr. Hata’s resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000155837022014299/0001558370-22-014299-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"db22611705","claim":"Nancy Valente was appointed as Director at Xencor Inc.","evidence_excerpt":"On September 8, 2022, Nancy Valente was appointed to the Board of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1326732/000155837022014299/0001558370-22-014299-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}